AlloVir (NASDAQ: ALVR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.800 | -0.690 | 0.1100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of AlloVir (NASDAQ: ALVR) through any online brokerage.
Other companies in AlloVir’s space includes: KalVista Pharmaceuticals (NASDAQ:KALV), bluebird bio (NASDAQ:BLUE), Precigen (NASDAQ:PGEN), Burning Rock Biotech (NASDAQ:BNR) and PepGen (NASDAQ:PEPG).
The latest price target for AlloVir (NASDAQ: ALVR) was reported by Piper Sandler on Thursday, May 19, 2022. The analyst firm set a price target for 34.00 expecting ALVR to rise to within 12 months (a possible 696.25% upside). 8 analyst firms have reported ratings in the last year.
The stock price for AlloVir (NASDAQ: ALVR) is $4.27 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for AlloVir.
AlloVir’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for AlloVir.
AlloVir is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.